$1.70
5.03% yesterday
Nasdaq, Aug 11, 10:02 pm CET
ISIN
US45257L1089
Symbol
IMMP

Immutep Ltd Sponsored ADR Stock price

$1.70
+0.05 3.03% 1M
-0.31 15.42% 6M
-0.47 21.66% YTD
-0.25 12.82% 1Y
-0.56 24.78% 3Y
+0.33 24.09% 5Y
-1.75 50.75% 10Y
-38.43 95.76% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
-0.09 5.03%
ISIN
US45257L1089
Symbol
IMMP
Industry

Key metrics

Basic
Market capitalization
$258.1m
Enterprise Value
$155.5m
Net debt
positive
Cash
$103.7m
Shares outstanding
1.5b
Valuation (TTM | estimate)
P/E
negative | negative
P/S
6,453.6 | 71.1
EV/Sales
3,887.6 | 43.9
EV/FCF
negative
P/B
2.3
Financial Health
Equity Ratio
94.0%
Return on Equity
-22.5%
ROCE
-31.7%
ROIC
-347.9%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$40.0k | $3.8m
EBITDA
- | $-39.0m
EBIT
$-35.7m | $-40.8m
Net Income
$-28.6m | $-41.7m
Free Cash Flow
$-30.2m
Growth (TTM | estimate)
Revenue
-76.5% | 4,612.6%
EBITDA
- | -
EBIT
-16.1% | -24.2%
Net Income
-9.0% | -49.5%
Free Cash Flow
-10.1%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -1,033.4%
EBIT
-101,680.7%
Net
-81,383.9% | -1,105.7%
Free Cash Flow
-86,060.9%
More
EPS
$0.0
FCF per Share
$0.0
Short interest
2.9%
Employees
31
Rev per Employee
$0.0
Show more

Is Immutep Ltd Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Immutep Ltd Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Immutep Ltd Sponsored ADR forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Immutep Ltd Sponsored ADR forecast:

Buy
89%
Hold
11%

Financial data from Immutep Ltd Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
0.04 0.04
76% 76%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.40 5.40
11% 11%
13,500%
- Research and Development Expense 30 30
23% 23%
75,625%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -36 -36
16% 16%
-89,244%
Net Profit -29 -29
9% 9%
-71,425%

In millions USD.

Don't miss a Thing! We will send you all news about Immutep Ltd Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immutep Ltd Sponsored ADR Stock News

Neutral
GlobeNewsWire
13 days ago
Media Release The pivotal TACTI-004 Phase III trial in first line non-small cell lung cancer (1L NSCLC) continues to build momentum and is recruiting patients at a growing number of activated clinical sites and countries Trial-in-Progress poster for TACTI-004 presented at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting Novel combination of efti with KEYTRUDA® (pembrolizuma...
Neutral
GlobeNewsWire
14 days ago
SYDNEY, AUSTRALIA, July 29, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an upcoming poster presentation for the pivotal TACTI-004 (KEYNOTE-F91) Phase III trial at the IASLC 2025 World Conference on Lung Cancer (WCLC), taking place in Barcelona, Spain, ...
Neutral
GlobeNewsWire
3 months ago
SYDNEY, AUSTRALIA, May 27, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces the investigator-initiated EFTISARC-NEO Phase II trial evaluating eftilagimod alfa (efti) with radiotherapy plus KEYTRUDA® (pembrolizumab) in the neoadjuvant setting for resectable ...
More Immutep Ltd Sponsored ADR News

Company Profile

Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. Its product is IMP321, which involves in clinical development for the treatment of breast cancer and melanoma. The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.

Head office Australia
CEO Marc Voigt
Employees 31
Founded 1987
Website www.immutep.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today